Rivastigimine potentially effective for Parkinson’s patients

Written by Alice Weatherston

A commonly prescribed dementia drug has been identified as potentially effective for helping to prevent debilitating falls and improving quality of life in individuals with Parkinson’s disease. The study was published recently in The Lancet Neurology and carried out at the University of Bristol (UK). Approximately 70% of individuals with Parkinson’s disease fall at least once a year and over one-third of these have frequent falls, making it a major issue for the 7 million Parkinson’s patients worldwide. Rivastigimine, which is regularly prescribed to patients with mild to moderate Alzheimer’s disease, was tested in a randomized, double-blind, placebo-controlled trial in...

To view this content, please register now for access

It's completely free